Showing 115 of 115on this page. Filters & sort apply to loaded results; URL updates for sharing.115 of 115 on this page
AZD9574 (Palacaparib) | PARP1 Inhibitor | CAS 2756333-39-6 | Selleck ...
Azd9574 | C21H22F2N6O2 | CID 162524593 - PubChem
AZD9574 selectively inhibits and traps PARP1. A, Chemical structure of ...
Azd9574 – Application in Therapy and Current Clinical Research
AZD9574 - a PARP1 inhibitor for BRCA-mutant tumors - drug annotation ...
AZD9574 for Advanced Solid Tumors Clinical Trial 2025 | Power
Badanie AZD9574 w monoterapii i w połączeniu z lekami ...
Abstract 2609: AZD9574 is a novel, brain penetrant PARP-1 selective ...
Study of the PARP inhibitor AZD9574 Alone and Combined with Other ...
A Study of AZD9574 as Monotherapy and in Combination with Anti-Cancer ...
Study of AZD9574 as monotherapy and in combination with anti-cancer ...
Breast Cancer UCLA Clinical Trial | Study of AZD9574 as Monotherapy and ...
恒瑞PARP1抑制剂出海带来的思考|抑制剂|首付款|实体瘤|恒瑞|专利|肿瘤|临床|-健康界
Palacaparib (AZD9574, AZD-9574)| PARP1 inhibitor | Probechem Biochemicals
How does AstraZeneca's PARP inhibitor differentiate?
2022 AACR | 小分子领域：合成致死细化&PARP-1深度开发！__财经头条
AZD-9574 is a potent and brain penetrant PARP1 inhibitor - Network of ...
AZD-9574 | PARP | TargetMol
RCSB PDB - 9ETR: Crystal structure of PARP1 catalytic domain bound to ...
【速递】PARP1抑制剂，恒瑞携手国际大药厂走向国际市场医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
解析具有CNS渗透性的PARP1抑制剂AZD9574分子设计及优化过程 - 知乎
阿斯利康第 2 款 PAPR1 高选择性抑制剂启动临床 6 月 14 日， 阿斯利康 在 ClinicalTrails.gov 上登记了 ...
合成致死再添新星！这款PARP1抑制剂突破3个关键点医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
AZ9482 is a Triple PARP1/2/6 Inhibitor - Network of Cancer Research
AZD5305 inhibits and traps selectively PARP1 in cells. A, Left ...
Preclinical Characterization of AZD9574, a Blood–Brain Barrier ...
AZD9574(AZD9574) - 药物靶点：PARP1_在研适应症：晚期恶性实体瘤_专利_临床_研发
卵巢癌新药有望提早获得FDA上市批准-美迪西生物医药
A novel 18F-labeled brain penetrant PET ligand for imaging poly(ADP ...
FDA撤销适应症，PARP下一步该怎么走？
Discovery of Pyrazolo[1,5,4-de]quinoxalin-2(3H)-one Derivatives as ...
PARP抑制剂 | PARP Inhibitor
阿斯利康介绍早期管线进展：下一代可透脑 PARP1 抑制剂、ADC、IO 疗法_临床_药物_数据
PK/PD/efficacy relationship of AZD5305 in a BRCA1m TNBC xenograft tumor ...
Patent Analysis of Jiangsu Hengrui's PARP1 Inhibitor HRS-1167
谁能接班奥拉帕利？_化合物_选择性_研究
RCSB PDB - 9ETQ: Crystal structure of PARP1 catalytic domain bound to ...
From Serendipity to Intention: Development of Brain-Penetrant PARP1 ...
XAV-939 | PARP 抑制剂 | 现货供应 | 美国品牌 | 免费采购电话400-668-6834
南通全益生物科技有限公司 -提供各类小分子剂定制合成，提供1000+库存
palacaparib | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY
Preserving ester-linked modifications reveals glutamate and aspartate ...
Discovery of 6-Fluoro-5-{4-[(5-fluoro-2-methyl-3-oxo-3,4 ...
ISSX 2022 - Hypha Discovery
百亿美元市场！领路者阿斯利康两手抓：奥拉帕利再获新适应症，下一代产品多款布局
Neuro-Oncology：PARPi增强H3K27M突变中线胶质瘤对放疗和NK细胞敏感性-MedSci.cn
AstraZeneca Stock: What's Next? (Rating Downgrade) (NASDAQ:AZN ...
Frontiers | BRCA1/2 alterations and reversion mutations in the area of ...
阿斯利康第 2 款 PAPR1 高选择性抑制剂启动临床_Insight_奥拉帕利_数据库
AZD3759,CAS:1626387-80-1
PPAR | DC Chemicals
阿斯利康国内首申下一代 PARP 抑制剂，可能带来哪些改变？ - 知乎
Pancreatic Cancer: Risk Management and Treatment Options
阿斯利康 B7-H4 ADC 国内临床即将启动！中国研发提速中_药物_Enhertu_研究
中国科学家突破H3K27M胶质瘤治疗困境：PARP抑制剂联合放疗激活免疫杀伤 - 知乎
Targeting DNA damage response to enhance cancer immunotherapy efficacy ...
十一月活性分子速递①: KT-474，RLY-2608，LY3522348与AZD9574 - 知乎
Cancer Treatment in People with RAD51D Gene Mutations
前沿热点 | 癌症的合成致死性靶向药物设计 - 知乎
STEAP2靶点新突破：阿斯利康启动STEAP2 ADC1/2 期临床 2025年9月18日， 阿斯利康 （AstraZeneca）在 ...
Discovery of clinical candidate AZD8421, a potent and highly selective ...
Gene context drift identifies drug targets to mitigate cancer treatment ...
谁能接班奥拉帕利？ - 知乎
Emerging Molecular PET Imaging for Cell Death in Neurodegenerative ...
Cancer Treatment in People with a PALB2 Mutation
JMC｜阿斯利康入脑KRAS抑制剂解析
PALB2 Gene Mutations: Risks, Management and Treatment
【JMC】四川大学杨涛/陈俐娟：新型大环类JAK2抑制剂，治疗骨髓增殖性肿瘤 - 知乎
AZD5305 selectively targets cancer cells with HRR-deficiency, inducing ...
7-(溴甲基)-8-氟-3-甲基喹喔啉-2(1H)-酮 – Eyougene Technology
Drug Hunter - drug discovery, distilled
美国化学会春季大会亮点：这些分子为老靶点带来新突破 @药明康德 内容团队编辑日前，在美国化学会（ACS）的春季2022会议“首次公布 ...
saruparib (AZD5305) / AstraZeneca
OR | Targeting DNA repair for cancer treatment: Lessons from PARP ...
美国化学会春季大会亮点：这些分子为老靶点带来新突破_腾讯新闻
罗氏揭秘PD-1-IL2v双靶融合蛋白的作用机制
